Hydroxamate sulfonamides as cd23 shedding inhibitors

Details Hydroxamate sulfonamides as cd23 shedding inhibitors Hydroxamate sulfonamides as cd23 shedding inhibitors

C - Chemistry, Metallurgy

07

D

C07D 295/22 (2006.01) A61K 31/496 (2006.01) A61P 37/08 (2006.01)

Patent

CA 2528317

A class of piperazine and related heterocyclic derivatives, substituted at the 4-position by a substituted aryl or heteroaryl moiety, and at the 1-position by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.

L'invention concerne une classe de pipérazine et de dérivés hétérocycliques associés, substituée à la position 4, par une fraction aryle ou hétéroaryle substituée, et à la position 1, par un groupe éthylsulfonyle, qui à son tour est substitué à la position 2 par une fraction d'acide hydroxamique et également par une variété de substituants alternatifs, constituant des inhibiteurs puissants de l'élimination du CD23, utiles pour le traitement et/ou pour la prévention de maladies allergiques, inflammatoires et néoplastiques.

Affiliated with

Also associated with

Rating

Hydroxamate sulfonamides as cd23 shedding inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxamate sulfonamides as cd23 shedding inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxamate sulfonamides as cd23 shedding inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1826838